You choose, we deliver
If you are interested in this story, you might be interested in others from The Journal Gazette. Go to www.journalgazette.net/newsletter and pick the subjects you care most about. We'll deliver your customized daily news report at 3 a.m. Fort Wayne time, right to your email.

Health

  • Bandits in Guinea steal suspected Ebola blood
    CONAKRY, Guinea – It was a highway robbery, but the bandits got more than they bargained for when they stopped a taxi in Guinea and made off with blood samples that are believed to be infected with the deadly Ebola virus.
  • Study will test survivors’ blood to treat Ebola
    A coalition of companies and aid groups announced plans Tuesday to test experimental drugs and collect blood plasma from Ebola survivors to treat new victims of the disease in West Africa.
  • Study
    CHICAGO – Curbing the routine use of preventive antibiotics before dental work may have contributed to a rise in heart valve infections in England, a new study suggests. In the U.S.
Advertisement

China Rx approval slow: Lilly boss

– China takes eight years longer on average to approve drugs than other major countries and U.S. drugmakers are looking at ways to help speed things up, Eli Lilly & Co. CEO John Lechleiter said.

“This is a drug lag that I hope we are able to close in the coming years, by working with Chinese authorities to speed up the process of doing clinical trials in China,” Lechleiter said last week in an interview in Beijing. The 59-year-old executive is spending the week in China to meet with government officials and business executives as chairman of the industry group Pharmaceutical Research and Manufacturers of America.

Lilly itself aims to conduct simultaneous late-stage tests in China for products such as the experimental diabetes drug dulaglutide, according to Lechleiter. The Indianapolis drugmaker wants to introduce more than a dozen medicines in China in the next five years, including drugs for diabetes and cancer, and aims to keep sales there growing 25 percent as they did last year, he said in March.

Drugmakers are working to expand their offerings in China, the world’s fastest-growing pharmaceuticals market, as revenue drops elsewhere, hurt by expiring patents on blockbusters. Lilly in October said quarterly earnings had missed analyst estimates after generic competition hurt revenue from the schizophrenia treatment Zyprexa, once the company’s top-selling drug.

Lechleiter said “prospects are good” for further expansion of Lilly’s drug-manufacturing operations in China. The company opened a second plant in June this year in the eastern city of Suzhou.

Advertisement